OPTIMI HEALTH CORP - OPTHF STOCK NEWS

Optimi Health Corp. has successfully uplisted to the OTCQB exchange, retaining its ticker symbol OPTHF. This exchange is designed for developing companies, requiring compliance with financial reporting and management certification. The OTCQB enhances visibility for investors, potentially improving liquidity and future capital access. In addition to trading on OTCQB, Optimi shares remain listed on the Canadian Securities Exchange (OPTI) and the German Börse Frankfurt (FRA: 8BN). Optimi is focused on health and wellness through mushroom products and has obtained research exemptions for Psilocybin and Psilocin development.

Optimi Health Corp. has received approval from Health Canada to proceed with a submission for a Phase 1 study of psilocybin. This follows discussions with the IMPACT Clinical Trials Accelerator at the University of Calgary. The study aims to explore the safety and efficacy of psilocybin, a natural compound derived from mushrooms, for mental health treatments. The formal application is expected to be submitted shortly, with trials anticipated to commence in Q3 2021. Optimi retains full ownership of the psilocybin product and intellectual property rights.

Optimi Health Corp. (CSE: OPTI, OTC: OPTHF) has signed a non-exclusive agreement with Vitasave, a leading Canadian natural health company, for product distribution. Vitasave will feature Optimi's functional mushroom products in its retail locations and online. Optimi is focused on the health and wellness market and operates a vertically integrated model for mushroom cultivation, extraction, and distribution. The company is also pursuing a dealer’s license for Psilocybin and Psilocin under Canadian regulations.

Optimi Health Corp. (OTC: OPTHF) has announced its common shares are now DTC eligible, facilitating quicker electronic clearing and settlement. This approval enhances accessibility for U.S. investors and positions Optimi for an upcoming up-listing to the OTCQB, which demands higher standards and transparency. CEO Michael Stier emphasized that this milestone broadens their market presence and provides a cost-effective method for trading. Optimi continues to develop its functional mushroom brand, focusing on health and wellness, while also pursuing regulatory compliance in Canada for psilocybin research.

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) has appointed Mr. Justin D. Kirkland as Chief Science Officer. With extensive expertise in natural products and drug formulation, Kirkland is expected to enhance Optimi's research in psilocybin formulations. The company is nearing completion of its 20,000 sq. ft. facility in Princeton, BC, and plans to conduct human dosing studies at the University of Calgary. Optimi emphasizes the use of all-natural ingredients, aiming for a competitive edge in the health and wellness market.

Optimi Health Corp. has partnered with Numinus Wellness Inc. to advance the development of a natural psilocybin capsule for a human clinical trial. A pre-clinical trial application has been submitted to Health Canada, with ongoing cultivation and validation studies at the Numinus lab in British Columbia. This initiative aims to produce standardized psilocybin dosages for various health conditions. Optimi will retain full ownership and intellectual property rights of the capsule.

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) has advanced its R&D program for a 100% Optimi-owned psychedelic capsule aimed at human clinical trials. Partnering with Numinus Wellness, Optimi is progressing towards Health Canada approvals for its psilocybin production. The firm emphasizes developing all-natural formulations, aiming for regulatory readiness and multiple revenue streams in addressing health conditions. The company has secured access to specialized laboratory services under the research agreement with Numinus, with all resulting intellectual property owned by Optimi.

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) is advancing the construction of its 20,000 sq. ft. production facility in Princeton, British Columbia. Recently, the company awarded contracts for critical interior finishing and technology installation. All required permits are secured, and advanced systems for HVAC and security are being implemented. The facility's design includes a Level 8 product vault for psilocybin, allowing secure storage with an initial capacity of 50kg, extendable to 1,250kg. City officials commend Optimi for diversifying the local economy and creating job opportunities.

Optimi Health has appointed Dr. Azim Jamal to its Advisory Board and Leah Hodges as Corporate Secretary. Dr. Jamal, a seasoned industry leader, has extensive experience in various business investments and previously served as CEO of Retirement Concepts. Leah Hodges brings over 16 years of corporate governance expertise. CEO Mike Stier emphasized the importance of governance for business success and welcomed the new appointments. Additionally, Optimi has signed an advisory agreement with fitness expert Harley Pasternak, issuing 50,000 shares initially, with up to 150,000 shares over three years, pending CSE approval.